Tags

Type your tag names separated by a space and hit enter

Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
J Atheroscler Thromb. 2005; 12(3):163-8.JA

Abstract

It is known that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) enhance the expression- of the low-density lipoprotein (LDL) receptor and lower the level of LDL cholesterol in the blood. But, a triglyceride (TG)-lowering effect is also observed during their administration. To clarify the possibility that statins enhance LPL activity and its mechanism, the effects of statins on the expression of LPL in adipocytes were studied. When statins (pravastatin, simvastatin, atorvastatin and pitavastatin) were added to the culture medium of mouse 3T3-L1 preadipocytes at final concentrations of 1 microM for 3 days, LPL activity increased. Pitavastatin increased the activity the most. Western and Northern blotting showed that LPL protein and m-RNA were strongly expressed on the addition of pitavastatin. With the addition of mevalonate (10 microM, 3 days), LPL activity weakened significantly. Statins, especially pitavastatin, increased the expression of LPL in 3T3-L1 preadipocytes. The TG-lowering effect of pitavastatin might be mediated by enhancement of LPL production in adipocytes.

Authors+Show Affiliations

Center of Diabetes, Endocrinology and Metabolism, School of Medicine, Toho University, Chiba, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16020917

Citation

Saiki, Atsuhito, et al. "Pitavastatin Enhanced Lipoprotein Lipase Expression in 3T3-L1 Preadipocytes." Journal of Atherosclerosis and Thrombosis, vol. 12, no. 3, 2005, pp. 163-8.
Saiki A, Murano T, Watanabe F, et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb. 2005;12(3):163-8.
Saiki, A., Murano, T., Watanabe, F., Oyama, T., Miyashita, Y., & Shirai, K. (2005). Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. Journal of Atherosclerosis and Thrombosis, 12(3), 163-8.
Saiki A, et al. Pitavastatin Enhanced Lipoprotein Lipase Expression in 3T3-L1 Preadipocytes. J Atheroscler Thromb. 2005;12(3):163-8. PubMed PMID: 16020917.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. AU - Saiki,Atsuhito, AU - Murano,Takeyoshi, AU - Watanabe,Fusako, AU - Oyama,Tomokazu, AU - Miyashita,Yoh, AU - Shirai,Kohji, PY - 2005/7/16/pubmed PY - 2005/10/21/medline PY - 2005/7/16/entrez SP - 163 EP - 8 JF - Journal of atherosclerosis and thrombosis JO - J Atheroscler Thromb VL - 12 IS - 3 N2 - It is known that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) enhance the expression- of the low-density lipoprotein (LDL) receptor and lower the level of LDL cholesterol in the blood. But, a triglyceride (TG)-lowering effect is also observed during their administration. To clarify the possibility that statins enhance LPL activity and its mechanism, the effects of statins on the expression of LPL in adipocytes were studied. When statins (pravastatin, simvastatin, atorvastatin and pitavastatin) were added to the culture medium of mouse 3T3-L1 preadipocytes at final concentrations of 1 microM for 3 days, LPL activity increased. Pitavastatin increased the activity the most. Western and Northern blotting showed that LPL protein and m-RNA were strongly expressed on the addition of pitavastatin. With the addition of mevalonate (10 microM, 3 days), LPL activity weakened significantly. Statins, especially pitavastatin, increased the expression of LPL in 3T3-L1 preadipocytes. The TG-lowering effect of pitavastatin might be mediated by enhancement of LPL production in adipocytes. SN - 1340-3478 UR - https://www.unboundmedicine.com/medline/citation/16020917/Pitavastatin_enhanced_lipoprotein_lipase_expression_in_3T3_L1_preadipocytes_ L2 - http://joi.jlc.jst.go.jp/JST.JSTAGE/jat/12.163?from=PubMed DB - PRIME DP - Unbound Medicine ER -